The adaptive immune response is a major determinant of the clinical outcome after SARS-
CoV-2 infection and underpins vaccine efficacy. T cell responses develop early and …

Cancer-specific T cells are required for effective anti-cancer immunity and have a central
role in cancer immunotherapy. However, emerging evidence suggests that only a small …

Immune-related adverse events, particularly severe toxicities such as myocarditis, are major
challenges to the utility of immune checkpoint inhibitors (ICIs) in anticancer therapy. The …

The kinetics of the immune changes in COVID-19 across severity groups have not been
rigorously assessed. Using immunophenotyping, RNA sequencing, and serum cytokine …

Basic science breakthroughs in T-cell biology and immune–tumor cell interactions ushered
in a new era of cancer immunotherapy. Twenty years ago, cancer immunoediting was …

Acute viral infections can have durable functional impacts on the immune system long after
recovery, but how they affect homeostatic immune states and responses to future …

Infection with SARS-CoV-2 causes wide range of disease severities from asymptomatic to
life-threatening disease. Understanding the contribution of immunological traits in immunity …

The emergence of novel variants of SARS-CoV-2 and their abilities to evade the immune
response elicited through presently available vaccination makes it essential to recognize the …

The T cell receptor (TCR) endows T cells with antigen specificity and is central to nearly all
aspects of T cell function. Each naïve T cell has a unique TCR sequence that is stably …

Mucosal infections pose a significant global health burden. Antigen-specific tissue-resident
T cells are critical to maintaining barrier immunity. Previous studies in the context of systemic …